PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance
Background: Acquired resistance of chemotherapy, especially cisplatin, is a major challenge in lung cancer treatment. We conducted this study to examine whether a cyclin D kinase 4/6 (CDK4/6) inhibitor, PD 0332991, could reverse cisplatin resistance in human lung cancer cells. In addition, we explor...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952807/ https://www.ncbi.nlm.nih.gov/pubmed/33534964 http://dx.doi.org/10.1111/1759-7714.13866 |
_version_ | 1783663811508568064 |
---|---|
author | Liu, Minghui Cui, Liyuan Li, Xin Xia, Chunqiu Li, Yongwen Wang, Rui Ren, Fan Liu, Hongyu Chen, Jun |
author_facet | Liu, Minghui Cui, Liyuan Li, Xin Xia, Chunqiu Li, Yongwen Wang, Rui Ren, Fan Liu, Hongyu Chen, Jun |
author_sort | Liu, Minghui |
collection | PubMed |
description | Background: Acquired resistance of chemotherapy, especially cisplatin, is a major challenge in lung cancer treatment. We conducted this study to examine whether a cyclin D kinase 4/6 (CDK4/6) inhibitor, PD 0332991, could reverse cisplatin resistance in human lung cancer cells. In addition, we explored the underlying mechanisms. Method: We used CCK‐8 assay to got the IC50 of PD‐0332991 and cisplatin in A549 and A549/CDDP respectively. CCK‐8 assay, CalcuSyn 2.0 software, cell cycle distribution and apoptosis used to identify PD‐0332991 could reverse the acquired resistance of cisplatin. At last, western‐blot used to show the mechanism of PD‐0332991 enhances the effects of cisplatin. Results: We found that PD‐0332991 potentiated cisplatin‐induced growth inhibition in both cisplatin‐sensitive (A549) and cisplatin‐resistant (A549/CDDP) cells via downregulation of the proliferation, induction of apoptosis (A549 increased to 7.06%; A549/CDDP increased to 7.03%), and G0/G1 cell cycle arrest (A549 increased to 9.15%; A549/CDDP increased to 49.92%). Western blot analysis revealed that PD‐0332991 enhance the effect of cisplatin through inhibit Rb‐E2Fs pathway. Conclusions: These findings suggest that PD‐0332991 could reverse the acquired resistance of cisplatin in lung cancer cells and provide a novel treatment strategy for lung cancer patients with cisplatin resistance. |
format | Online Article Text |
id | pubmed-7952807 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-79528072021-03-17 PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance Liu, Minghui Cui, Liyuan Li, Xin Xia, Chunqiu Li, Yongwen Wang, Rui Ren, Fan Liu, Hongyu Chen, Jun Thorac Cancer Original Articles Background: Acquired resistance of chemotherapy, especially cisplatin, is a major challenge in lung cancer treatment. We conducted this study to examine whether a cyclin D kinase 4/6 (CDK4/6) inhibitor, PD 0332991, could reverse cisplatin resistance in human lung cancer cells. In addition, we explored the underlying mechanisms. Method: We used CCK‐8 assay to got the IC50 of PD‐0332991 and cisplatin in A549 and A549/CDDP respectively. CCK‐8 assay, CalcuSyn 2.0 software, cell cycle distribution and apoptosis used to identify PD‐0332991 could reverse the acquired resistance of cisplatin. At last, western‐blot used to show the mechanism of PD‐0332991 enhances the effects of cisplatin. Results: We found that PD‐0332991 potentiated cisplatin‐induced growth inhibition in both cisplatin‐sensitive (A549) and cisplatin‐resistant (A549/CDDP) cells via downregulation of the proliferation, induction of apoptosis (A549 increased to 7.06%; A549/CDDP increased to 7.03%), and G0/G1 cell cycle arrest (A549 increased to 9.15%; A549/CDDP increased to 49.92%). Western blot analysis revealed that PD‐0332991 enhance the effect of cisplatin through inhibit Rb‐E2Fs pathway. Conclusions: These findings suggest that PD‐0332991 could reverse the acquired resistance of cisplatin in lung cancer cells and provide a novel treatment strategy for lung cancer patients with cisplatin resistance. John Wiley & Sons Australia, Ltd 2021-02-03 2021-03 /pmc/articles/PMC7952807/ /pubmed/33534964 http://dx.doi.org/10.1111/1759-7714.13866 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Liu, Minghui Cui, Liyuan Li, Xin Xia, Chunqiu Li, Yongwen Wang, Rui Ren, Fan Liu, Hongyu Chen, Jun PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance |
title |
PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance |
title_full |
PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance |
title_fullStr |
PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance |
title_full_unstemmed |
PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance |
title_short |
PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance |
title_sort | pd‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952807/ https://www.ncbi.nlm.nih.gov/pubmed/33534964 http://dx.doi.org/10.1111/1759-7714.13866 |
work_keys_str_mv | AT liuminghui pd0332991combinedwithcisplatininhibitsnonsmallcelllungcancerandreversalofcisplatinresistance AT cuiliyuan pd0332991combinedwithcisplatininhibitsnonsmallcelllungcancerandreversalofcisplatinresistance AT lixin pd0332991combinedwithcisplatininhibitsnonsmallcelllungcancerandreversalofcisplatinresistance AT xiachunqiu pd0332991combinedwithcisplatininhibitsnonsmallcelllungcancerandreversalofcisplatinresistance AT liyongwen pd0332991combinedwithcisplatininhibitsnonsmallcelllungcancerandreversalofcisplatinresistance AT wangrui pd0332991combinedwithcisplatininhibitsnonsmallcelllungcancerandreversalofcisplatinresistance AT renfan pd0332991combinedwithcisplatininhibitsnonsmallcelllungcancerandreversalofcisplatinresistance AT liuhongyu pd0332991combinedwithcisplatininhibitsnonsmallcelllungcancerandreversalofcisplatinresistance AT chenjun pd0332991combinedwithcisplatininhibitsnonsmallcelllungcancerandreversalofcisplatinresistance |